Orthopedic robotics is still in the early stages of adoption with SmartTRAK estimating that more than 25% of US hospitals have a robot and that fewer than 18% of TKA procedures in the US will have been performed robotically by YE2020. However, Stryker* noted in its Q320 earnings call that orthopedic robotic adoption (MAKO*) has started to reach an inflection point with an uptick in momentum that includes increasing interest, multiple installations in centers, placements into teaching hospitals and a shift to ASCs. Increasing competition from Zimmer Biomet’s* ROSA* and the launch of Smith & Nephew’s* CORI* second-generation robotic platform, has helped to push accounts that were thinking about purchasing a robot to follow through.
Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 CAS Ortho Market Recap* are:
Ortho robotics companies have been nimble in shifting business models for the placement of robots during the coronavirus pandemic to meet the needs of hospitals through increasing placements based on implant volume commitments in Q220. Q320 saw a rebound in elective procedures and higher demand for medical capital products. Stryker management believes that ...
*The entire article, including revenue, shares and links can only be viewed by SmartTRAK subscribers to this module.
To see all the exciting things coming to SmartTRAK in 2021, including additions to our Computer Assisted Surgery module, or to request more info about what SmartTRAK can do for you, just click the button below.